Oncology & Cancer

People with leukemia have a weakened immune system due to the disease itself and treatment, which leads to an increased susceptibility to infections. In a revised guideline, experts summarize the findings of the past ten years on all viruses that cause respiratory infections: How dangerous are they in detail? How are they diagnosed? Are hygiene measures necessary? What treatment and vaccination strategies are available?

Triple-negative breast cancer (TNBC), the deadliest breast cancer subtype, disproportionately affects African American women—but until now, they have been underrepresented in genomic studies aimed at identifying the genetic mutations driving the disease.

Patients with intermediate stage primary liver cancer who received a vaccine of dendritic cells saw a longer time without tumor progression in response to standard treatment, according to a new study led by the University of Birmingham.

Exercise is a cornerstone of good health and evidence shows it can even help prevent cancers returning following treatment. But new findings are raising an unexpected question: could very high-volume endurance training carry its own risks?

Researchers at the Leibniz Institute for Plasma Science and Technology (INP) have collaborated with partners at Greifswald University Hospital and University Medical Center Rostock to demonstrate that cold plasma can effectively combat tumor cells even in deeper tissue layers.

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease progression in patients with advanced triple-negative breast cancer (TNBC), one of the most aggressive and hard-to-treat forms of breast cancer.

From virtual counselors that can hear depression creeping into a person’s voice to smart watches that can detect stress, artificial intelligence is poised to revolutionize mental health care for patients with breast cancer.

A team of researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has successfully treated a rare and aggressive T-cell lymphoma that developed after CAR T-cell therapy for multiple myeloma, marking a first in the field of hematologic cancer research. The findings were published in the New England Journal of Medicine.

Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research from the University of Texas MD Anderson Cancer Center.

A new study focused on multiple myeloma, the second most common blood cancer, may lead to better ways to group patients by the state of their DNA and define new subtypes of disease to better predict treatment strategies and outcomes.